Abstract: The invention relates to an immunoglobulin composition reduced in thrombogenic agents and to methods for its preparation. One method comprises subjecting an immunoglobulin containing solution to a negative cation exchanger chromatography at a pH in the range of higher than 3.8 to equal to or lower than 5.3. The solution can also be subjected to a negative anion exchanger chromatography at a pH in the range of 7 to 8.2.
Type:
Grant
Filed:
April 3, 2015
Date of Patent:
October 24, 2017
Assignee:
Omrix Biopharmaceuticals Ltd.
Inventors:
Roni Mintz, Oleg Belyaev, Israel Nur, Liliana Bar, Roberto Meidler
Abstract: The present application relates to an immunoglobulin preparation comprising anti-hepatitis B antibodies for subcutaneous administration and to uses thereof, including methods for treating, preventing and/or reducing a disease, disorder or condition associated with hepatitis B virus.
Abstract: The present invention is directed to a method for manufacturing a cross-linked gelatin sponge having a surface by providing a cross-linked gelatin sponge, wetting the surface of the sponge by applying a sufficient amount of liquid comprising a protein or peptide active ingredient, wherein a sufficient amount of liquid is one that retains the flexibility of the sponge even after drying. The sponge is then dried the sponge to obtain a flexible, dry and ready to use cross linked gelatin sponge having a layer of protein or peptide active ingredient on the surface thereof.
Type:
Grant
Filed:
September 29, 2015
Date of Patent:
August 30, 2016
Assignee:
Omrix Biopharmaceuticals Ltd.
Inventors:
Israel Nur, Liliana Bar, Guy Tomer, Eyal Sheetrit
Abstract: A concentrated, immunoglobulin composition for treating subjects vaccinated against or infected with a pathogenic microorganism, is made by (a) selecting a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism; (b) identifying very high titer individuals by determining the level of specific antibodies immunoreactive with the pathogenic microorganism in the blood of the individuals; (c) combining blood from the very high titer individuals; and (d) purifying and/or concentrating the product of step (c). A concentrated immunoglobulin composition can include specific antibodies immunoreactive with a pathogenic microorganism, wherein the titer of specific antibodies is at least 5 times higher than the average titer of specific antibodies of a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism. The composition has a relatively high protein concentration and a low percentage of protein aggregates.
Abstract: The invention relates to the use of viral inactivated-plasma cryoprecipitate concentrate (VIPCC) comprising a suitable fibronactin/fibrinogen ratio for treating a spine disease, disorder or condition such as intervertebral disc degeneration.
Abstract: The invention relates to an in vitro immunoassay for quantifying thrombin in a sample comprising anti-thrombin III (AT-III) and thrombin. The method comprises the following steps: contacting the sample with a small molecule that recognizes the substrate binding site of thrombin; contacting the thrombin with a thrombin specific antibody raised against a thrombin blocked in the active site; and measuring the level of bound antibody.
Abstract: The invention relates to purification of an intact, non-degraded macromolecule from a biological mixture comprising the macromolecule in the presence of its lytic enzyme. The method comprises providing the biological mixture as a heterogeneous mixture comprising the lytic enzyme, at least partially, in soluble form and the macromolecule, at least partially, in non-soluble form; batch-wise contacting the heterogeneous mixture with an immobilized inhibitor of the lytic enzyme; increasing the solubility of the macromolecule in the mixture; and removing the immobilized inhibitor from the mixture.
Type:
Grant
Filed:
June 26, 2012
Date of Patent:
May 3, 2016
Assignee:
Omrix Biopharmaceuticals Ltd.
Inventors:
Roberto Meidler, Nina Raver-Shapira, Liliana Bar, Oleg Belyaev, Israel Nur
Abstract: The present invention relates to a fibrin matrix, its preparation and use for effectively sealing a defect in a mucosa or other moist tissue.
Abstract: A device for administering injections includes a housing having an upper end, a lower end including a bottom surface with an injection needle opening, and an axis extending between the upper and lower ends. The device includes an injection needle disposed within the housing for moving between a retracted position and an extended position.
Abstract: A method is described for the measurement of thrombin activity in the presence of fibrinogen, or for the measurement of the functionality of fibrinogen in the presence of thrombin.
Abstract: The invention relates to an applicator tip for spraying and/or mixing at least two fluids that react together, the tip comprising: at least two fluid conduits for carrying the at least two fluids, each conduit having at least one outlet opening, the openings are positioned substantially on a same plane; at least two gas conduits for carrying a gas volume, each gas conduit comprises a proximal gas tube and a distal gas tube, each distal gas tube is bent as compared to the position of the proximal gas tube, and each distal gas tube has one gas opening positioned distal from the plane of the outlet openings; and a housing for accommodating the at least two fluid conduits and the at least two gas conduits. The device allows efficient spraying in close proximity to a surface.
Abstract: Provided are methods for lyophilization of an aqueous thrombin solution, thrombin solutions for use in such lyophilization methods, and solid thrombin compositions produced by such methods.
Type:
Grant
Filed:
March 4, 2013
Date of Patent:
December 15, 2015
Assignee:
Omrix Biopharmaceuticals Ltd.
Inventors:
Roberto Meidler, Oleg Belyaev, Liliana Bar, Israel Nur
Abstract: The invention relates to an in vitro immunoassay for quantifying thrombin in a sample comprising anti-thrombin III (AT-III) and thrombin. The method comprises the following steps: contacting the sample with a small molecule that recognizes the substrate binding site of thrombin; contacting the thrombin with a thrombin specific antibody raised against a thrombin blocked in the active site; and measuring the level of bound antibody.
Abstract: The invention relates to an immunoglobulin composition reduced in thrombogenic agents and to methods for its preparation. One method comprises subjecting an immunoglobulin containing solution to a negative cation exchanger chromatography at a pH in the range of higher than 3.8 to equal to or lower than 5.3. The solution can also be subjected to a negative anion exchanger chromatography at a pH in the range of 7 to 8.2.
Type:
Grant
Filed:
May 14, 2012
Date of Patent:
May 5, 2015
Assignee:
Omrix Biopharmaceuticals, Ltd.
Inventors:
Roni Mintz, Oleg Belyaev, Israel Nur, Liliana Bar, Roberto Meidler
Abstract: The present invention is directed to a method for manufacturing a cross-linked gelatin sponge having a surface by providing a cross-linked gelatin sponge, wetting the surface of the sponge by applying a sufficient amount of liquid comprising a protein or peptide active ingredient, wherein a sufficient amount of liquid is one that retains the flexibility of the sponge even after drying. The sponge is then dried the sponge to obtain a flexible, dry and ready to use cross linked gelatin sponge having a layer of protein or peptide active ingredient on the surface thereof.
Type:
Grant
Filed:
March 20, 2013
Date of Patent:
March 17, 2015
Assignee:
Omrix Biopharmaceuticals Ltd.
Inventors:
Israel Nur, Liliana Bar, Guy Tomer, Eyal Sheetrit
Abstract: The invention relates to the use of viral inactivated-plasma cryoprecipitate concentrate (VIPCC) comprising a suitable fibronectin/fibrinogen ratio for treating a spine disease, disorder or condition such as intervertebral disc degeneration.
Abstract: The present invention relates to a fibrin matrix, its preparation and use for effectively sealing a defect in a mucosa or other moist tissue.
Abstract: The present application relates to an immunoglobulin preparation comprising anti-hepatitis B antibodies for subcutaneous administration and to uses thereof, including methods for treating, preventing and/or reducing a disease, disorder or condition associated with hepatitis B virus.